Track the Everest Medicines Ltd. stock price and the full insider trade history of the company, a listed equity based in Hong Kong. Shares trade on the HK market, under the supervision of HKEX. Operating in the Health Care sector, Everest Medicines Ltd. has logged 20 reports. Market capitalisation: €10.2bn. The latest transaction was reported on 19 August 2026 (Other). Among the most active insiders: FU WEI. All data is free.
20
Insider Decl.
n/a
Thresholds
€126m
16 ops.
Buy Volume
n/a
n/a
Sell Volume
36Σ signal
Buys €126mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,220 of 28,717 companies
32.7
score / 100
Value
25
Quality
40
FCF yld-4.0%
Earn yld-2.7%
EV/EBITDA·
ROE-1.2%
Gross mgn69%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing innovative treatments for serious diseases in Asia. The company is listed on the Hong Kong Stock Exchange.